Johnson & Johnson Elmiron Lawsuit Update
In 2020, several lawsuits were filed against Johnson & Johnson and Janssen Pharmaceuticals claiming that Elmiron–a drug prescribed to treat painful bladder syndrome–caused them to suffer severe vision complications such as retinal damage and macular degeneration. Here, the pharmaceutical liability attorneys at Peter Angelos, P.C. provide an update on the lawsuits.
Elmiron, a drug prescribed to treat pain and discomfort associated with chronic bladder conditions, is at the center of a growing number of lawsuits filed against Johnson & Johnson (J&J). Patients who took Elmiron can suffer from a range of complications including vision loss, paracentral scotoma, difficulty adjusting to dim or dark lighting, and vision dimming. Plaintiffs’ attorneys also allege their clients developed severe vision complications including maculopathy, retinal hemorrhage, macular degeneration and vision loss after years of taking the drug.
Elmiron Lawsuits Claim J&J Concealed the Risks
Lawsuits specifically allege that J&J failed to warn the public about the risks of severe vision impairment and other eye conditions, despite knowing the potential adverse effects and allegedly receiving reports from doctors regarding the same. Several complaints cite studies from the 1980s and 1990s which showed that Elmiron, or pentosan polysulfate sodium (PPS), could be linked to vision ailments. They also claim that manufacturers like J&J knew that the human body did not easily absorb Elmiron, and that substantial amounts of the drug could be excreted or absorbed into cells in the retina.
Plaintiffs have alleged that despite having knowledge of these findings, J&J and Janssen Pharmaceuticals purposely covered up the risks of taking Elmiron, which led to a significant delay in the plaintiffs discovering the link between Elmiron and eye damage. Many plaintiffs also suggest that at the time the drug was prescribed to them, the drug’s packaging and labels had no warning of these potential effects. Janssen has since updated the warning label on the medication.
Elmiron Case Updates
In December, 2020, the United States Judicial Panel on Multidistrict Litigation (JPML) heard arguments to consolidate the cases into a multidistrict litigation. The JPML has granted consolidation, and litigation will proceed in the District of New Jersey. Litigators expect the number of cases within the MDL to grow to hundreds as the lawsuit develops.
Your Rights Related to Elmiron and Prescription Pharmaceuticals
Pharmaceuticals manufacturers who withhold or conceal information regarding a medication’s potential adverse effects knowingly put patients at risk of severe health complications or death. The patients prescribed Elmiron to treat harmful bladder conditions may have been knowingly denied by its manufacturers their right to weigh the benefits and risks of taking the drug. The experienced pharmaceutical liability attorneys at Peter Angelos, P.C., are dedicated to seeking justice for victims who suffer at the hands of corporations who fail to carry out the appropriate measures of thorough testing and transparency.
If you or someone you know now suffers from vision impairment after taking Elmiron to treat their bladder condition, contact the Baltimore office of Peter Angelos, P.C. immediately to request a free consultation.